Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
NAALADL1 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Profile neighbors
LOC101926951 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GALT - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
CSRNP3 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GPR65 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
AMER2 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
LOC100289061 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GEO DataSets Gene Profile neighbors Chromosome neighbors
SIRT3 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
SPATA4 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
GLOD5 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
OPALIN - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
ACTA2 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
EPRS - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
BMS1P5 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
HFE - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
CFAP52 - Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on